Announcements Trials
Browse Landscape

Phase

Phase 1/2 4

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Other solid neoplasm 4Gynecologic 2Gastrointestinal 2Breast 1

Conditions

Leukemia, Myeloid, Acute 246Precursor Cell Lymphoblastic Leukemia-Lymphoma 147Myelodysplastic Syndromes 144Leukemia, Lymphocytic, Chronic, B-Cell 140Leukemia 128Multiple Myeloma 118Lymphoma 116Lymphoma, Non-Hodgkin 112Recurrence 80Hematologic Neoplasms 77Melanoma 68Hodgkin Disease 68Leukemia, Myelogenous, Chronic, BCR-ABL Positive 67Lymphoma, B-Cell 61Lymphoma, Mantle-Cell 52Lymphoma, Large B-Cell, Diffuse 50Lymphoma, Follicular 50Burkitt Lymphoma 41Ovarian Neoplasms 40Neoplasms 39Myeloproliferative Disorders 39Neoplasm Metastasis 34Lymphoma, B-Cell, Marginal Zone 30Graft vs Host Disease 29Neoplasms, Plasma Cell 28Carcinoma, Non-Small-Cell Lung 27Breast Neoplasms 27Leukemia, Biphenotypic, Acute 25Primary Myelofibrosis 24Anemia, Refractory, with Excess of Blasts 23

Interventions

Cisplatin 57Pemetrexed 46pembrolizumab 18Nivolumab 15Carboplatin 15Gemcitabine 14Cyclophosphamide 13Radiotherapy 10Drug Therapy 9atezolizumab 8Platinum 7Ipilimumab 7Doxorubicin 7durvalumab 61,2-diaminocyclohexaneplatinum II citrate 6tremelimumab 5sodium thiosulfate 5Vinorelbine 5Radiotherapy, Intensity-Modulated 5Interleukin-2 5Chemotherapy, Adjuvant 5Cerebral Decortication 5sargramostim 4fludarabine 4defactinib 4aldesleukin 4tumor necrosis factor-alpha, CNGRC fusion protein, human 3cediranib 3Photochemotherapy 3Neoadjuvant Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × fludarabine × Clear all
NCT07510815 2026-04-06

DUAL-MESO-NK

Beijing Biotech

Phase 1/2 Recruiting
36 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
57 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
6 enrolled
BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02414945 2023-01-10

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

University Health Network, Toronto

Phase 1/2 Completed
9 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡